alopecia

Posts

Global Alopecia Drugs Market Insights Report

Alopecia Market Pipeline H1 Review

Alopecia Market Pipeline H1 Review Products in Clinical Stage, Methodology, Therapeutic Landscape and R&D Progress

Alopecia Market – Pipeline Review H1 2018, provides detail overview of Alopecia development scenario.

This report delivers top-line data relating to the Alopecia Market pipeline landscape and also includes important players/vendors, Drugs Profile, Therapeutics Development, Molecule Type, Mechanism of Action.

Alopecia Market report additionally, provides an overview of key players involved in therapeutic development for Alopecia Market and features dormant and discontinued projects. The report also covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.

Ask for PDF Sample of this Alopecia Market Report https://www.absolutereports.com/enquiry/request-sample/11716319

Some of The Key Players of Alopecia Market Pipeline Therapeutics Include: Aclaris Therapeutics Inc, Allergan Plc, Almirall SA, AndroScience Corp, Berg LLC, BiologicsMD Inc, BirchBioMed Inc, Brickell Biotech Inc, Bristol-Myers Squibb Co, Cassiopea SpA and More

Alopecia Market Report Highlights:

Alopecia Market Pipeline report guide covers comprehensive information on the therapeutics under development for Alopecia Market complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Alopecia Market pipeline helps in identifying and tracking emerging players in the market and their portfolios enhance decision-making capabilities and help to create effective counter-strategies to gain competitive advantage.

The Scope of Alopecia Market:

Alopecia Market pipeline support provides a snapshot of the global therapeutic landscape.
The pipeline guide reviews key companies involved in Alopecia therapeutics and enlists all their major and minor projects.

Alopecia pipeline help to covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

Alopecia Market pipeline adviser to evaluates therapeutics based on a mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The guide is built using data and information sourced from company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real-time basis.

Reasons to buy of Alopecia Market:

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with the potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Alopecia Market
Classify potential new clients or partners in the target demographic.

Price of Report: $ 2000 (Single User License)

Purchase Report at https://www.absolutereports.com/purchase/11716319

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Alopecia Market pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from a pipeline.

Alopecia Market Pipeline H1 Review

Source

Global Androgenic Alopecia Drug Market 2018

Global Androgenic Alopecia Drug Market 2018

Global Androgenic Alopecia Drug Market 2018 Analysis and Overview by QY Market Research

QY Market Research has recently published the latest report titled Global Androgenic Alopecia Drug Market Report 2018. Androgenic Alopecia Drug Market report gives complete global coverage of Androgenic Alopecia Drug market data from 2013 to 2018.

This Androgenic Alopecia Drug report starts with the review of Androgenic Alopecia Drug industry chain structure and defines the Androgenic Alopecia Drug business growth rate, trend, current status, investigates global Androgenic Alopecia Drug market share/volume and forecast up to 2023.

Worldwide Androgenic Alopecia Drug market report analyzes world’s main regions and additionally provides Androgenic Alopecia Drug industry top player’s Profiles/Analysis (Allergan,Inc., Histogen,Inc., R-TechUeno,Ltd., HygeiaTherapeutics,Inc., SWITCHBiotechLLC, PolichemS.A., KasiakResearchPvt.Ltd. ), regional coverage, product insights, Androgenic Alopecia Drug product types and product application insights.

Global Androgenic Alopecia Drug Market esteemed at XX million USD in last year(2017) and Androgenic Alopecia Drug market report expected it to reach XX million USD in forthcoming years during(2018-2023). The Worldwide Androgenic Alopecia Drug Market volume is predicted to boost a spectacular growth at XXX% of CAGR during the forecast duration.

The years considered to anticipate the market size of Androgenic Alopecia Drug are Base Year: 2017, Estimated Year: 2018, History Period/Year(last 5 years Historical data): 2013-2017, and Forecast Period/Year 2018 to 2023.

Top Manufacturers/Companies Included in Global Androgenic Alopecia Drug Market Report are: Allergan, Inc., Histogen, Inc., R-TechUeno, Ltd., HygeiaTherapeutics, Inc., SWITCHBiotechLLC, PolichemS.A., KasiakResearchPvt.Ltd.

Androgenic Alopecia Drug Industry Regional Analysis and Market Insights:

Regionally Androgenic Alopecia Drug market report isolated globally into some major key Regions, with revenue (million USD), Androgenic Alopecia Drug sales data (K Units), Androgenic Alopecia Drug market share (%) and growth rate of Androgenic Alopecia Drug industry for mentioned regions.

The Androgenic Alopecia Drug study report contains Androgenic Alopecia Drug market in North America(United States, Canada, Mexico), Androgenic Alopecia Drug business in Central & South America(Argentina, Chile, Brazil), Androgenic Alopecia Drug industry in Europe(UK, Spain, Germany, Italy, France, and Russia), Androgenic Alopecia Drug marketplace in the Middle East & Africa(Turkey, Egypt, Saudi Arabia, and South Africa) and Androgenic Alopecia Drug market in Asia-Pacific(India, China, Japan, South Korea, Indonesia, Singapore, Australia). The Androgenic Alopecia Drug Report additionally gives Key Partners with Androgenic Alopecia Drug producer, Androgenic Alopecia Drug Subcomponent Makers, Androgenic Alopecia Drug Traders/Wholesalers/Distributors, Downstream Vendors and Androgenic Alopecia Drug Industry Unions.

On the basis of Product Type, the Global Androgenic Alopecia Drug industry report shows the product price (USD/Unit), sales volume (K Units), Androgenic Alopecia Drug market share (%), production, Androgenic Alopecia Drug revenue (Million USD), and growth rate of each type, mainly split into; RK-023, Refagro, RCH-01, SM-04554, HYG-440, Others.

On the basis of Applications/end users, the Global Androgenic Alopecia Drug Market mainly focuses on the outlook and status for top Androgenic Alopecia Drug applications/end users, Androgenic Alopecia Drug market size, Share, consumption (sales), sales volume and growth rate for each application, including; Clinic, Hospital, HomeUse.

This Androgenic Alopecia Drug Market 2018 Study Report offers:

• A review of The Worldwide market for Global Androgenic Alopecia Drug Market and related advancements.
• In-depth analyses of Global market trends, with data from 2013, estimates for 2014 and 2017, and prediction of CAGR through 2023.
• A Clear Forecast prospect for geographical segments (regions) and also sub-segments will extend at the most exalted rate.
• Essential techniques for growth, and the demand for new applications and new products.
• Brand Procedure, Target Clients and Pricing Technique.
• Competitive landscaping of key market players.

List of Chapters (TOC) of Global Androgenic Alopecia Drug Market 2018 Study Report Contains the Following Points:

Chapters 1. Androgenic Alopecia Drug Industry Overview.
Chapters 2. Worldwide Androgenic Alopecia Drug Market Competition by Prime Players/Providers, Product Type, and Application.
Chapters 3. United States Androgenic Alopecia Drug Market Share and Androgenic Alopecia Drug Sales Volume by Key Players, Product Type & Application.
Chapters 4. Europe Androgenic Alopecia Drug Market Share, Growth Rate, & Sales.
Chapters 5. India Androgenic Alopecia Drug (Deals Cost, Value and Volume).
Chapters 6. China Androgenic Alopecia Drug Industry (Sales Price, Value and Volume).
Chapters 7. Japan Androgenic Alopecia Drug Marketplace Growth Rate, Sales Price Trend, Income.
Chapters 8. South-east Asia Androgenic Alopecia Drug Market (Sales Price, Value and Volume).
Chapters 9. Global Androgenic Alopecia Drug Providers/Players Profiles and Deals Information.
Chapters 10. Production Cost Analysis of Androgenic Alopecia Drug business.
Chapters 11. Androgenic Alopecia Drug Downstream Consumers, Sourcing Method, Industrial Chain.
Chapters 12. Worldwide Androgenic Alopecia Drug Traders/Distributors, Marketing Strategy Analysis.
Chapters 13. Androgenic Alopecia Drug Industry Impact Factors Analysis.
Chapters 14. Worldwide Androgenic Alopecia Drug Market Forecast (2018-2023).
Chapters 15. Worldwide Androgenic Alopecia Drug Market Research and Development Status, Research Findings and Conclusion.
Chapters 16. Appendix.

Ask Full Table of Content (TOC) with Graphs, Figures, Tables Here: http://www.qymarketresearch.com/

Global Androgenic Alopecia Drug Market 2018

Source

Global Alopecia Drugs Market Insights Report

Alopecia pipeline review

Alopecia pipeline review H2 2018 just published

If you are want to study the Alopecia industry or intend to be, then this guide will provide you comprehensive outlook. It’s vital for you to keep your knowledge up to date by keeping research and development (R&D) of major players.

If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide requirement according to your needs.

Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body.

Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Key Players included in the research study are Aclaris Therapeutics Inc, Allergan Plc, Almirall SA, AndroScience Corp, Berg LLC, BiologicsMD Inc, BirchBioMed Inc, Brickell Biotech Inc, Bristol-Myers Squibb Co, Cassiopea SpA, Concert Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Dong-A Socio Holdings Co Ltd, Eli Lilly and Co, Energenesis Biomedical Co Ltd, Follica Inc, Histogen Inc, Japan Tobacco Inc, JW Pharmaceutical Corp, Kuhnil Pharmaceutical Co Ltd, Lee’s Pharmaceutical Holdings Ltd, Medivir AB, NovaLead Pharma Pvt Ltd, OliX Pharmaceuticals Inc, Pfizer Inc, Portola Pharmaceuticals Inc, Quark Pharmaceuticals Inc, RXi Pharmaceuticals Corp, Samumed LLC, Taisho Pharmaceutical Holdings Co Ltd & Tigo GmbH.

The guide features dormant and discontinued projects and covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively.

Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Alopecia pipeline guide helps in identifying and tracking emerging and major players moves in the market and their portfolios, enhances decision-making capabilities and helps to create effective marketing strategies to gain a competitive advantage in healthcare and pharmaceuticals industry. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The data and information sourced from the databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the latest key developments are captured on a real-time basis.

Extracts of Chapters from Alopecia – Pipeline Review, H2 2018
Chapter 1, to describe the definition, overview and Therapeutics Development of Alopecia.
Chapter2, to analyze the pipeline overview of companies, Universities/Institutes and the product development under by companies, Universities/Institutes.
Chapter3, Therapeutics Assessment of Alopecia by Target, Mechanism of Action, Route of Administration and by Molecule Type.
Chapter4, to display company profile involved in Therapeutics Development.
Chapter5, Drug profile product description, Mechanism of action and R&D Progress of Alopecia.
Chapter 6,7, to describe Alopecia Appendix, Methodology, Coverage, Secondary Research, Primary Research, Expert Panel Validation and Contact Us.

Objective of this study

– To provides a snapshot of the global therapeutic landscape of Alopecia.
– To reviews pipeline therapeutics for Alopecia by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprises, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Alopecia therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Alopecia therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews the latest news related to pipeline therapeutics for Alopecia

This research report helps to

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Alopecia.
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Alopecia pipeline review

Source

Hair Loss and Balding in Women

Nolopecia Balding and Prostate Cancer

Balding and Prostate Cancer: Lilac Corp reviews a study and recommends Nolopecia, a natural treatment for hair loss

All natural hair loss supplement sold by Lilac Corp

Lilac Corp reviews a study that tested a possible link between early hair loss and prostate cancer.

Nolopecia, targets the latent viruses in the body. This helps the body maintain a normal level of the 5alpha-R, DHT, and AR proteins. A normal level of these proteins stimulates hair growth.”

A study showed that men with very early onset balding are more likely to develop aggressive prostate cancer, and at a younger age [1]. Some prostate cancers are more dangerous than others. Prostate cancer and androgenic alopecia, also called male pattern baldness, are both dependent on androgen hormones.

The study surveyed 1,941 men and found that men balding at age 20 years had a 50% higher chance of developing aggressive prostate cancer.

Also, these men were diagnosed with cancer an average of 16 months earlier than non-balding men.

Men balding at age 40 years and older, or non-balding men did not have the increased risk. Research like this is important because it helps to identify groups of men with a higher risk for aggressive cancer.

Men who are at a higher risk can perform regular screening tests for prostate cancer and should be followed up closely with their doctor.

For men (and women), who suffer from hair loss and balding, Lilac Corp recommends the natural treatment Nolopecia. Lilac Corp is the company that invented the highly effective and unique antiviral natural treatments Gene-Eden-VIR and Novirin.

The new treatment, called Nolopecia, targets the latent viruses in the body. This helps the body maintain a normal level of the 5alpha-R, DHT, and AR proteins. A normal level of these proteins stimulates hair growth.

There are many treatments for hair loss on the market.

However, only Nolopecia targets the latent viruses that cause the increase in 5alpha-R, DHT, and AR observed in people with hair loss and balding.

About Lilac Corp:

Lilac Corp specializes in the development of biology-based patent protected natural treatments. Currently, Lilac Corp is selling four products: Gene-Eden-VIR, Novirin, Nolopecia, and Noacnin. Lilac Corp ships its products to more than 100 countries around the world.

What makes Lilac Corp special is that all its products are tested in clinical studies that follow FDA guidelines. To ensure transparency, the results of the clinical studies are published in leading scientific journals. Lilac Corp also offers a 90-day money back guarantee.

Source:
[1] Papa, N., MacInnis, R., English, D., Bolton, D., Davis, I., & Lawrentschuk, N. et al. (2017). Early-onset baldness and the risk of aggressive prostate cancer: findings from a case-control study. Cancer Causes & Control, 29(1), 93-102. doi: 10.1007/s10552-017-0981-0

Source

Improved Minoxidil Formulation Safe, Effective for Androgenetic Alopecia

hair transplant market

Global and Chinese Alopecia Industry – 2017

Global and Chinese Alopecia Industry – 2017

Healthcare Market Reports has been published the new research report today.

The ‘Global and Chinese-Alopecia Industry – 2017’ is a professional and in-depth study on the current state of the global Alopecia industry with a focus on the Chinese market.

The report provides key statistics on the market status of the Alopecia manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

 Global and Chinese Alopecia Industry

Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology.

Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2012-2017 market shares for each company.

Through the statistical analysis, the report depicts the global and Chinese total market of the Alopecia industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2017-2022 market development trends of the Alopecia industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

In the end, the report makes some important proposals for a new project of the Alopecia-Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2012-2022 global and Chinese-Alopecia industry covering all important parameters.

Source

alopecia market

Alopecia Market: Global Investment Analysis

Alopecia Market: Global Investment Analysis, Size, Challenges, Opportunities and Forecast by 2022

According to the Global Alopecia Market report, the Alopecia Market accounted a value of $8.12 billion in 2015 and is projected to reach a value $12.53 billion at the end of 2022.

The Global Alopecia Market report covers the Alopecia Market in a comprehensive manner, across all parameters such as types, applications, users, top players, and regions.

The report further covers the drivers, restraints and trends in the Alopecia Market for the customer to understand the intricacies of the Alopecia Market which will help them create an efficient plan of action to grow at the fastest rate across the globe.

The Global Alopecia Market is expected to keep rising at a CAGR of 17.6% for the forecast period of 2017 – 2022. The Global Alopecia Market report provides the customer an accurate analysis of the Alopecia Market to assist them in planning their market entry or expansion.

The forecast projection is compiled by a team of subject matter experts and market research professionals to ensure that the information is accurate and presented in an easy to consume tables, charts, and graphs.

For the customer to be able to plan for a significant period, the Global Alopecia Market report covers projections up to 2022.

The current market scenarios and laws under which the market operates in make it easier to understand how the market will play out for the forecast period. The current trends in the market and the drivers and restrains affecting the market might change with the times.

The top players covered in the report include the following:

Lifes2good, Kirkland Signature, Johnson & Johnson., Dr. Reddy’s Laboratories., Cipla., Alpecin., Vitabiotics., Sun Pharma., Phyto Ales Groupe., Phyto Ales Group, and Merck & Co.

Request a Free Sample of The Report: http://www.orbisresearch.com/contacts/request-sample/184998

The report covers a detailed analysis of each majorly impacting player in the Alopecia Market such as the company profile, the latest developments by the player in the Alopecia Market, and the product portfolio of the player currently available in the Alopecia Market, as well as the regions they operate in majorly.

Alopecia Types Covered:
Alopecia Universalis
Alopecia Totalis
Alopecia Areata

Products Covered:
Shampoos and Conditioners
Vitamins and Supplements
Other Products
Gels and Oils
Serums

Treatment Types Covered:
Hair Transplant Services
Low Level Laser Therapy
Oral Treatment
Topical Treatment
Injectable
Plasma Therapy
Steroids
Injectable Fillers
Other Treatment Types

Genders Covered:
Male
Female

End Users Covered:
Homecare Settings
Aesthetic Clinics
Dermatology And Trichology Clinics
Hospitals
Other End Users

The regions covered in the Global Alopecia Market report include North America (US, Canada, Mexico), Europe (Germany, UK, Italy, France, Spain, Rest of Europe), Asia Pacific (Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific), South America (Argentina, Brazil, Chile, Rest of South America), and Middle East & Africa (Saudi Arabia, UAE, Qatar, South Africa, Rest of Middle East & Africa).

The Global Alopecia Market report covers the SWOT analysis of the Alopecia Market along with key developments in the market that will be helpful for the customer. Anyone with either academic of business interest in the Alopecia Market, the report will definitely by handy.

About

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Source

hair loss supplements

Pediatric Alopecia Areata Severity Linked to Serum Vitamin D

Pediatric Alopecia Areata Severity Linked to Serum Vitamin D

For pediatric patients with alopecia areata, vitamin D is negatively correlated with disease severity, number of patches, and disease duration, according to a study published online in the Journal of Cosmetic Dermatology.

Mehmet Unal, MD, and Gulsum Gonulalan, MD, from the Konya Numune Hospital in Turkey, examined vitamin D status in 20 pediatric patients with alopecia areata and 34 pediatric healthy controls. The authors assessed the correlation between vitamin D status and disease severity, number of patches, and disease duration.

The researchers found that the mean serum 25-hydroxyvitamin D concentration was 15.47±7.66 and 11.09±10.53 ng/mL in patients and controls, respectively; no statistically significant difference was seen between the groups (P =.084).

Significant, negative correlations were seen for vitamin D concentration with the Severity of Alopecia Tool score (P <.001; r, -0.831), number of patches (P <.001; r, -0.989), and disease duration (P <.001 and r, -0.997).

“Vitamin D deficiency is not the only etiologic factor in alopecia areata pathogenesis, but in the presence of other etiological factors, this deficiency can aggravate alopecia areata severity, and thus, vitamin D supplementation may be beneficial in treatment of pediatric alopecia areata,” the authors write.

Source